The revenue guidance cut and sharp profitability decline signal near-term headwinds for PHARM. Monitor Q3 RUCONEST stabilization and Joenja growth trajectory, as well as the leniolisib CVID data readout in Q4 2026 which could provide a significant pipeline catalyst. The improved operating expense guidance suggests management is taking cost actions, but the core RUCONEST franchise faces ongoing competitive pressure from oral on-demand HAE treatments.
Price Chart
Executive Summary
Pharming Group reported Q2 2026 total revenues of $90.2M, down 3% YoY, with RUCONEST declining 10% to $72.3M while Joenja grew 40% to $17.9M. Operating profit collapsed to $1.3M from $10.8M a year ago, impacted by $4.9M in manufacturing-related inventory impairments and the France site closure. The company lowered its 2026 total revenue guidance by $30M to $375M-$395M, though it improved operating expense guidance by $15M to $315M-$320M. The stock will move on the revenue guidance cut and the deteriorating profitability, partially offset by Joenja's strong growth and upcoming leniolisib data in CVID expected in Q4 2026.
Key Financial Metrics
Key Facts
- Q2 2026 total revenues decreased 3% YoY to $90.2M
- RUCONEST revenue fell 10% YoY to $72.3M, though up 24% QoQ
- Joenja revenue grew 40% YoY to $17.9M
- Operating profit dropped 88% to $1.3M from $10.8M YoY
- 2026 total revenue guidance lowered by $30M to $375M-$395M (0-5% growth)
- Operating expense guidance improved by $15M to $315M-$320M
- Cash and equivalents decreased to $159.5M from $171.8M at end of Q1 2026
- Leniolisib Phase II data in CVID expected in Q4 2026
- PDUFA date for pediatric APDS label expansion set for October 24, 2026
Financial Impact
Revenue guidance cut of $30M (7-8% reduction from prior midpoint) and operating profit decline of 88% YoY in Q2
Risk Factors
- Continued RUCONEST market share erosion from oral on-demand HAE competitors
- Manufacturing-related inventory impairments may recur
- Cash burn of $12.2M in H1 2026 reduces financial flexibility
- Leniolisib CVID trial failure would remove a key pipeline growth driver
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3335752 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Press Release | — | awaiting T+20 | — | — |
Sep 11, 2026 6w ago | Press Release | — | awaiting T+20 | — | — |
Aug 13, 2026 10w ago | Press Release | — | awaiting T+20 | — | — |
Jul 30, 2026 12w ago | Press Release | — | awaiting T+20 | — | — |
Jul 16, 2026 14w ago | Press Release | — | awaiting T+20 | — | — |
May 28, 2026 21w ago | Press Release | — | awaiting T+20 | — | — |
May 7, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
May 7, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
Apr 23, 2026 26w ago | Press Release | — | awaiting T+20 | — | — |
Apr 7, 2026 29w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers